11β-hydroxylase deficiency epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 7: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Prevalence=== | ===Prevalence=== | ||
The prevalence of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency in United States is approximately 1 per 100,000 individuals. | |||
===Incidence=== | ===Incidence=== | ||
CAH due to 11-beta-hydroxylase deficiency accounts for 5 to 8 percent of all cases of congenital adrenal hyperplasia. It is estimated that CAH due to 11-beta-hydroxylase deficiency occurs in 1 in 100,000 to 200,000 newborns. This condition is more common in Moroccan Jews living in Israel, occurring in approximately 1 in 5,000 to 7,000 newborns | CAH due to 11-beta-hydroxylase deficiency accounts for 5 to 8 percent of all cases of congenital adrenal hyperplasia. It is estimated that CAH due to 11-beta-hydroxylase deficiency occurs in 1 in 100,000 to 200,000 newborns. This condition is more common in Moroccan Jews living in Israel, occurring in approximately 1 in 5,000 to 7,000 newborns | ||
| Line 15: | Line 15: | ||
===Gender=== | ===Gender=== | ||
* Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency affects male and female equally. | |||
===Race=== | ===Race=== | ||
* Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency usually affects individuals of the Jewish race. | |||
===Developed Countries=== | ===Developed Countries=== | ||
===Developing Countries=== | ===Developing Countries=== | ||
Revision as of 20:26, 26 January 2016
|
Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency Microchapters |
|
Differentiating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
11β-hydroxylase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of 11β-hydroxylase deficiency epidemiology and demographics |
|
FDA on 11β-hydroxylase deficiency epidemiology and demographics |
|
CDC on 11β-hydroxylase deficiency epidemiology and demographics |
|
11β-hydroxylase deficiency epidemiology and demographics in the news |
|
Blogs on 11β-hydroxylase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency |
|
Risk calculators and risk factors for 11β-hydroxylase deficiency epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Epidemiology and Demographics
Prevalence
The prevalence of congenital adrenal hyperplasia due to 11β-hydroxylase deficiency in United States is approximately 1 per 100,000 individuals.
Incidence
CAH due to 11-beta-hydroxylase deficiency accounts for 5 to 8 percent of all cases of congenital adrenal hyperplasia. It is estimated that CAH due to 11-beta-hydroxylase deficiency occurs in 1 in 100,000 to 200,000 newborns. This condition is more common in Moroccan Jews living in Israel, occurring in approximately 1 in 5,000 to 7,000 newborns
Case Fatality Rate
Age
Gender
- Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency affects male and female equally.
Race
- Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency usually affects individuals of the Jewish race.